Search clinical trials for: Deferasirox (Novartis Pharma)

Total 2447 results

University of Erlangen-Nürnberg Medical School
Novartis Pharmaceuticals

Terminated

Exjade-Early-Trial

Myelodysplastic Syndromes

Germany
China Medical University Hospital

Completed

Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients

Beta-thalassemia Major
Federico II University

Completed

Prediction of Tumor Shrinkage in Acromegaly

Acromegaly

Italy
Tianjin Medical University Second Hospital
Tianjin Medical University General Hospital; Tianjin First Central Hospital; The...

Not yet recruiting

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

Prostate Cancer

China
French National Agency for Research on AIDS and...

Completed

Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients

Cryoglobulinemia Vasculitis

France
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Transfusion-dependent Anemia

Egypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
Institut fuer anwendungsorientierte Forschung und...
Novartis Pharmaceuticals; University Medical Center Goettingen

Completed

Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. (RABIMO)

Macular Degeneration

Germany
Novartis Pharmaceuticals

Completed

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (Jupiter)

Non-transfusion-dependent Thalassemia | Transfusion-dependent Thalassemia

Egypt, Turkey, Thailand, Lebanon, Morocco, Saudi Arabia, Vietnam
DisperSol Technologies, LLC

Completed

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

Thalassemia Major

Thailand, United States
Novartis Pharmaceuticals

Withdrawn

Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia (CENTAurus)

Thalassemia (Transfusion Delendent)
University Hospital, Bonn

Completed

Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study (RIP)

Age Related Macular Degeneration

Germany
Assistance Publique - Hôpitaux de Paris
Association pour l'Etude des Fonctions Digestives (AEFD)

Unknown

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

Porphyria Cutanea Tarda

France
Novartis Pharmaceuticals

Completed

Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Low and Int 1-risk Myelodysplastic Syndrome

Germany, Canada, Korea, Republic of, Sweden, Spain, China, Argentina, Italy, United Kingdom, Algeria
Novartis

Completed

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Beta-Thalassemia | Hemosiderosis

Egypt, Lebanon, Oman, Saudi Arabia, Syrian Arab Republic
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia (THETIS)

Non-transfusion Dependent Thalassemia

Thailand, Turkey, Italy, Greece, China, United Kingdom, Lebanon, Tunisia
City of Hope Medical Center

Terminated

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Iron Overload | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States
Crolll Gmbh
University of Magdeburg; Estimate, GmbH

Completed

The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (DEFINE)

Non-alcoholic Steatohepatitis | Increased Iron Storage / Disturbed Distribution

Germany
University of Oxford

Completed

Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day (AL3vs5)

Plasmodium Falciparum Infection

Myanmar
Novartis Pharmaceuticals

Completed

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Transfusional Hemosiderosis

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Iron Overload | Hereditary Hemochromatosis

United States, Germany, Italy, Australia, Canada, France
Masonic Cancer Center, University of Minnesota

Terminated

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Iron Overload | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Novartis Pharmaceuticals

Completed

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Myelodysplastic Syndromes | Beta-Thalassemia

Hungary
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease (TROS)

Sickle Cell Disease

Netherlands
Abramson Cancer Center of the University of Pennsylvania

Completed

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

High Risk MDS or AML Patients

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

Myelodysplastic Syndromes | Transfusion Dependent Iron Overload

Germany
Novartis

Completed

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Myelodysplastic Syndromes | Hemoglobinopathies | Diamond-Blackfan Anemia | Transfusional Iron Overload | Other Inherited or Acquired Anaemia | MPD Syndrome | Other Rare Anaemias

Australia
Novartis Pharmaceuticals

Completed

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload (CORDELIA)

Transfusional Hemosiderosis | Transfusional Iron Overload

Taiwan, Turkey, Egypt, United Kingdom, Thailand, Canada, China, Italy, Cyprus, Lebanon, United Arab Emirates
Elliott Vichinsky

Completed

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Iron Overload | Thalassemia

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Transfusional Hemosiderosis | Chronic Anemia

Japan, Turkey, Spain, Poland, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study (THALASSA)

Non-transfusion Dependent Thalassemia

Greece, Taiwan, Italy, United Kingdom, Lebanon, Turkey, Malaysia, Thailand, United States
Children's Hospital Los Angeles
Novartis Pharmaceuticals

Terminated

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

Anemia, Sickle Cell | Transfusion Hemosiderosis

United States
Novartis Pharmaceuticals

Completed

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Transfusional Hemosiderosis

Egypt, Spain, United Kingdom, Jordan
Novartis Pharmaceuticals

Completed

Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload

Iron Overload

Spain
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

Iron Overload

China
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions

Influenza, Human

Germany
Hormozgan University of Medical Sciences

Completed

Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload

Iron Overload | Thalassemia | Transfusion Related Complications

Iran, Islamic Republic of
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

Hereditary Hemochromatosis

Belgium, France, Russian Federation, Romania, Slovakia, Spain, Switzerland
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
University of Pisa
IRCCS Burlo Garofolo; University of Genova

Recruiting

Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT

Iron Overload

Italy
Children's Hospital of Philadelphia
Ann & Robert H Lurie Children's Hospital of Chicago; The Cooley's Anemia Foundation...

Completed

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Thalassemia Major With Severe Transfusional Iron Overload

United States
Novartis Pharmaceuticals

Completed

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Iron Overload | Sickle Cell Disease | Hemolytic Anemia

United States, Canada
Norwegian University of Science and Technology
St. Olavs Hospital

Completed

Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications

Uveitis | Macular Edema | Anterior Uveitis | Iridocyclitis | Iritis

Norway
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload (HYPERION)

Cardiac Iron Overload

Taiwan, Egypt, Thailand, Turkey, United Kingdom, Italy, Canada, Greece
Novartis Pharmaceuticals

Completed

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Anemia, Sickle Cell

United States
San Diego Radiosurgery

Unknown

Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

Prostate Cancer

United States
University Hospital, Bonn

Completed

Oxytocin and the Processing of Social Stress-Associated Chemosignals

Healthy Volunteers
Boston University
Innovations for Poverty Action

Completed

Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative

Cardiovascular Disease | Breast Cancer | Asthma | Diabetes Type II
St. Josef Hospital Bochum

Completed

Effects of Intraarterial Octreotide on Pancreatic Texture

Pancreatic Fistula

Germany
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditions

United States
Ain Shams University

Unknown

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Sickle Cell Disease | Beta-thalassemia Major | Iron Hemosiderosis

Egypt

Search clinical trials for: Deferasirox (Novartis Pharma)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations